Infections, Respiratory Tract Clinical Trial
Official title:
A Two-Part Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Repeat IV Doses of GSK2140944 in Healthy Adult Subjects.
GSK2140944 belongs to the Bacterial Type II Topoisomerase Inhibitor (BTI) class of antibiotics. GSK2140944 has demonstrated in vitro and in vivo activity against Gram positive pathogens including methicillin resistant Staphylococcus aureus (MRSA) and Gram-negative pathogens associated with respiratory tract, skin and soft tissue infections including isolates resistant to existing classes of antimicrobials.
GSK2140944 belongs to the Bacterial Type II Topoisomerase Inhibitor (BTI) class of antibiotics. GSK2140944 has demonstrated in vitro and in vivo activity against Gram positive pathogens including methicillin resistant Staphylococcus aureus (MRSA) and Gram-negative pathogens associated with respiratory tract, skin and soft issue infections including isolates resistant to existing classes of antimicrobials. This study will be the first administration of GSK2140944 as an intravenous (IV) formulation in humans and will be conducted in two (2) parts. Single IV doses will be explored in Part A and repeat IV doses will be explored in Part B. In addition, this study will evaluate the absolute bioavailability of an oral capsule formulation as compared to the IV formulation in Part A. Both study parts will investigate the safety, tolerability and pharmacokinetic profile of GSK2140944 in healthy adult subjects. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02202187 -
A Single Oral Escalating Dose Study of GSK2140944 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT02257398 -
Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01706315 -
This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profile of Repeat Oral Doses of GSK2140944 in Healthy Adult Subjects
|
Phase 1 | |
| Completed |
NCT02000765 -
A Study to Investigate the Recovery, Excretion and Pharmacokinetics of [14C]-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects
|
Phase 1 | |
| Completed |
NCT04600752 -
Study to Evaluate the Safety and Clinical Efficacy of Augmentin® Extra Strength-600 in Children With Acute Otitis Media in India
|
Phase 4 | |
| Terminated |
NCT01292213 -
A Study to Identify and Characterise Bacteria Causing Chronic Cough Among Children in United Kingdom
|
N/A | |
| Completed |
NCT01772238 -
Bioequivalence Study of an Amoxicillin-Clavulanic
|
Phase 1 | |
| Completed |
NCT02169583 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects
|
Phase 1 | |
| Completed |
NCT01353768 -
Zanamivir Aqueous Solution Compassionate Use Program Retrospective Chart Review Study
|
N/A | |
| Completed |
NCT01767571 -
Bioequivalence Study of Cephalexin Suspension 250
|
Phase 1 | |
| Completed |
NCT01767532 -
Bioequivalence Study of Cephalexin Suspension 125
|
Phase 1 | |
| Completed |
NCT01510938 -
Probiotics in Respiratory Tract Infections in Children
|
Phase 2 | |
| Completed |
NCT00354965 -
Pharmacokinetic Profiles Of Amoxicillin 2000 mg And Clavulanate 125 mg In Adolescent Patients
|
Phase 1 | |
| Completed |
NCT02688361 -
A Bioequivalence Study of an Acetylcysteine 2% Oral Solution Versus a Reference Fluimucil 2% Oral Solution
|
Phase 1 | |
| Withdrawn |
NCT02678234 -
An Efficacy and Safety Study of Theraflu Day Powder as Oral Solution for Cold and Flu
|
Phase 3 | |
| Withdrawn |
NCT02730364 -
An Efficacy and Safety Study of Theraflu Night Powder as Oral Solution for Cold and Flu
|
Phase 3 | |
| Completed |
NCT01767584 -
Bioequivalence Study of Cephalexin Tablets 1g
|
Phase 1 |